Cargando…

Measuring quality of life impairment in skeletal muscle channelopathies

BACKGROUND AND PURPOSE: Fatigue and pain have been previously shown to be important determinants for decreasing quality of life (QoL) in one report in patients with non-dystrophic myotonia. The aims of our study were to assess QoL in skeletal muscle channelopathies (SMC) using INQoL (individualized...

Descripción completa

Detalles Bibliográficos
Autores principales: Sansone, V A, Ricci, C, Montanari, M, Apolone, G, Rose, M, Meola, G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492909/
https://www.ncbi.nlm.nih.gov/pubmed/22607270
http://dx.doi.org/10.1111/j.1468-1331.2012.03751.x
_version_ 1782249187555934208
author Sansone, V A
Ricci, C
Montanari, M
Apolone, G
Rose, M
Meola, G
author_facet Sansone, V A
Ricci, C
Montanari, M
Apolone, G
Rose, M
Meola, G
author_sort Sansone, V A
collection PubMed
description BACKGROUND AND PURPOSE: Fatigue and pain have been previously shown to be important determinants for decreasing quality of life (QoL) in one report in patients with non-dystrophic myotonia. The aims of our study were to assess QoL in skeletal muscle channelopathies (SMC) using INQoL (individualized QoL) and SF-36 questionnaires. METHODS: We administered INQoL and SF-36 to 66 Italian patients with SMC (26: periodic paralysis, 36: myotonia congenita and 4: Andersen-Tawil) and compared the results in 422 patients with myotonic dystrophies (DM1: 382; and DM2: 40). RESULTS: (i) INQoL index in SMC is similar to that in DMs (P = 0.79). (ii) Patients with myotonia congenita have the worst perception of QoL. (iii) Myotonia has the most detrimental effect on patients with myotonia congenita, followed by patients with DM2 and then by patients with DM1 and hyperkalemic periodic paralysis. (iv) Pain is a significant complaint in patients with myotonia congenita, hypokalemic periodic paralysis and DM2 but not in DM1. (v) Fatigue has a similar detrimental effect on all patient groups except for patients with hyperkalemic periodic paralysis in whom muscle weakness and myotonia more than fatigue affect QoL perception. (vi) Muscle symptoms considered in INQoL correlate with physical symptoms assessed by SF-36 (R from −0.34 to −0.76). CONCLUSIONS: QoL perception in patients with SMC is similar to that of patients with DMs, chronic multisystem disabling conditions. Our results provide information to target treatment and health care of these patients. The sensitivity of INQoL to changes in QoL in the SMC needs to be further explored in longitudinal studies.
format Online
Article
Text
id pubmed-3492909
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-34929092012-11-09 Measuring quality of life impairment in skeletal muscle channelopathies Sansone, V A Ricci, C Montanari, M Apolone, G Rose, M Meola, G Eur J Neurol Original Articles BACKGROUND AND PURPOSE: Fatigue and pain have been previously shown to be important determinants for decreasing quality of life (QoL) in one report in patients with non-dystrophic myotonia. The aims of our study were to assess QoL in skeletal muscle channelopathies (SMC) using INQoL (individualized QoL) and SF-36 questionnaires. METHODS: We administered INQoL and SF-36 to 66 Italian patients with SMC (26: periodic paralysis, 36: myotonia congenita and 4: Andersen-Tawil) and compared the results in 422 patients with myotonic dystrophies (DM1: 382; and DM2: 40). RESULTS: (i) INQoL index in SMC is similar to that in DMs (P = 0.79). (ii) Patients with myotonia congenita have the worst perception of QoL. (iii) Myotonia has the most detrimental effect on patients with myotonia congenita, followed by patients with DM2 and then by patients with DM1 and hyperkalemic periodic paralysis. (iv) Pain is a significant complaint in patients with myotonia congenita, hypokalemic periodic paralysis and DM2 but not in DM1. (v) Fatigue has a similar detrimental effect on all patient groups except for patients with hyperkalemic periodic paralysis in whom muscle weakness and myotonia more than fatigue affect QoL perception. (vi) Muscle symptoms considered in INQoL correlate with physical symptoms assessed by SF-36 (R from −0.34 to −0.76). CONCLUSIONS: QoL perception in patients with SMC is similar to that of patients with DMs, chronic multisystem disabling conditions. Our results provide information to target treatment and health care of these patients. The sensitivity of INQoL to changes in QoL in the SMC needs to be further explored in longitudinal studies. Blackwell Publishing Ltd 2012-11 2012-05-19 /pmc/articles/PMC3492909/ /pubmed/22607270 http://dx.doi.org/10.1111/j.1468-1331.2012.03751.x Text en European Journal of Neurology © 2012 European Federation of Neurological Societies http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Original Articles
Sansone, V A
Ricci, C
Montanari, M
Apolone, G
Rose, M
Meola, G
Measuring quality of life impairment in skeletal muscle channelopathies
title Measuring quality of life impairment in skeletal muscle channelopathies
title_full Measuring quality of life impairment in skeletal muscle channelopathies
title_fullStr Measuring quality of life impairment in skeletal muscle channelopathies
title_full_unstemmed Measuring quality of life impairment in skeletal muscle channelopathies
title_short Measuring quality of life impairment in skeletal muscle channelopathies
title_sort measuring quality of life impairment in skeletal muscle channelopathies
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3492909/
https://www.ncbi.nlm.nih.gov/pubmed/22607270
http://dx.doi.org/10.1111/j.1468-1331.2012.03751.x
work_keys_str_mv AT sansoneva measuringqualityoflifeimpairmentinskeletalmusclechannelopathies
AT riccic measuringqualityoflifeimpairmentinskeletalmusclechannelopathies
AT montanarim measuringqualityoflifeimpairmentinskeletalmusclechannelopathies
AT apoloneg measuringqualityoflifeimpairmentinskeletalmusclechannelopathies
AT rosem measuringqualityoflifeimpairmentinskeletalmusclechannelopathies
AT meolag measuringqualityoflifeimpairmentinskeletalmusclechannelopathies
AT measuringqualityoflifeimpairmentinskeletalmusclechannelopathies